Lilly Gains Approval for Zepbound in Sleep Apnea Care
Eli Lilly has achieved a monumental medical advancement through ZEPBOUND (tirzepatide), establishing revolutionary benchmarks within sleep disorder clinical practice. The historic FDA approves ZEPBOUND for obstructive sleep apnea authorization in December 2024 introduces the first pharmaceutical solution specifically developed to address this challenging sleep-related respiratory condition....
0 Yorumlar 0 hisse senetleri 1K Views 0 önizleme
Sponsorluk

Bundas24 Ads

Get your products and services across the globe as little as $ 1.00 with Bundas 24 Ads.

Sponsorluk